Clinical Trial Detail

NCT ID NCT02637531
Title A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Infinity Pharmaceuticals, Inc.
Indications

melanoma

carcinoma

lung non-small cell carcinoma

Therapies

Pembrolizumab

IPI-549

Age Groups: adult

No variant requirements are available.